pioglitazone has been researched along with Carcinogenesis in 3 studies
Pioglitazone: A thiazolidinedione and PPAR GAMMA agonist that is used in the treatment of TYPE 2 DIABETES MELLITUS.
pioglitazone : A member of the class of thiazolidenediones that is 1,3-thiazolidine-2,4-dione substituted by a benzyl group at position 5 which in turn is substituted by a 2-(5-ethylpyridin-2-yl)ethoxy group at position 4 of the phenyl ring. It exhibits hypoglycemic activity.
Carcinogenesis: The origin, production or development of cancer through genotypic and phenotypic changes which upset the normal balance between cell proliferation and cell death. Carcinogenesis generally requires a constellation of steps, which may occur quickly or over a period of many years.
Excerpt | Relevance | Reference |
---|---|---|
"In LNCaP, a human androgen-dependent prostate cancer cell line, PGZ also inhibited cyclin D1 expression and the activation of both p38 MAPK and NFκB." | 5.43 | Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis. ( Kato, H; Kobayashi, M; Kuno, T; Mori, Y; Nagano, A; Nagayasu, Y; Naiki-Ito, A; Suzuki, S; Takahashi, S, 2016) |
"Furthermore, treating breast cancer cells with pioglitazone that stabilizes the 3Cys-1His cluster of NAF-1 results in a similar effect on mitochondrial iron and reactive oxygen species accumulation." | 1.43 | Breast cancer tumorigenicity is dependent on high expression levels of NAF-1 and the lability of its Fe-S clusters. ( Bai, F; Darash-Yahana, M; Geiger, T; Jennings, PA; Karmi, O; Lu, M; Mittler, R; Nechushtai, R; Onuchic, JN; Pikarsky, E; Pozniak, Y; Sohn, YS; Song, L; Tamir, S, 2016) |
"In LNCaP, a human androgen-dependent prostate cancer cell line, PGZ also inhibited cyclin D1 expression and the activation of both p38 MAPK and NFκB." | 1.43 | Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis. ( Kato, H; Kobayashi, M; Kuno, T; Mori, Y; Nagano, A; Nagayasu, Y; Naiki-Ito, A; Suzuki, S; Takahashi, S, 2016) |
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 3 (100.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Sohn, YS | 2 |
Tamir, S | 2 |
Song, L | 2 |
Michaeli, D | 1 |
Matouk, I | 1 |
Conlan, AR | 1 |
Harir, Y | 1 |
Holt, SH | 1 |
Shulaev, V | 1 |
Paddock, ML | 1 |
Hochberg, A | 1 |
Cabanchick, IZ | 1 |
Onuchic, JN | 2 |
Jennings, PA | 2 |
Nechushtai, R | 2 |
Mittler, R | 2 |
Darash-Yahana, M | 1 |
Pozniak, Y | 1 |
Lu, M | 1 |
Karmi, O | 1 |
Bai, F | 1 |
Pikarsky, E | 1 |
Geiger, T | 1 |
Suzuki, S | 1 |
Mori, Y | 1 |
Nagano, A | 1 |
Naiki-Ito, A | 1 |
Kato, H | 1 |
Nagayasu, Y | 1 |
Kobayashi, M | 1 |
Kuno, T | 1 |
Takahashi, S | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone, and Incretin Based Therapy[NCT02882477] | Phase 2/Phase 3 | 20 participants (Anticipated) | Interventional | 2016-12-31 | Not yet recruiting | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
3 other studies available for pioglitazone and Carcinogenesis
Article | Year |
---|---|
NAF-1 and mitoNEET are central to human breast cancer proliferation by maintaining mitochondrial homeostasis and promoting tumor growth.
Topics: Animals; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Cell Survival; Fema | 2013 |
Breast cancer tumorigenicity is dependent on high expression levels of NAF-1 and the lability of its Fe-S clusters.
Topics: Animals; Biomarkers, Tumor; Breast Neoplasms; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; | 2016 |
Pioglitazone, a Peroxisome Proliferator-Activated Receptor γ Agonist, Suppresses Rat Prostate Carcinogenesis.
Topics: Adenocarcinoma; Animals; Body Weight; Carcinogenesis; Cell Line, Tumor; Cell Proliferation; Disease | 2016 |